Digging into the Exertis Almo Merger and What it Means for the Future of AV

The Pro AV industry has experienced exponential growth as venues and public spaces reopened due to the waning threat of COVID within the United States. With technology driving innovative advances within the industry, companies are working to find ways to meet customer needs while tackling business challenges and turning visions into reality.

Pro AV Today host Ben Thomas spoke with Sam Taylor, COO of Exertis Almo about the organization’s recent acquisition of Almo and what this means to the future of the organization.

“We’re bringing together two great companies and we’re using best practices from both companies so we’re becoming better than we each were separately. Combined now, it gives us scale. We have a hundred salespeople across the US calling on our customer base. We went from seven warehouses to fourteen that we can draw inventory from for our customers,” explained Taylor.

There are simply too many benefits to these two companies coming together to list. For example, there are now twenty-five business development managers dedicated to serving client needs, up from eighteen previously.

But how will this merger affect industry staples like the popular E4 Experience expo that was previously run by Almo? It’s a big question since it is considered a cornerstone event in the industry that occurs multiple times a year showcasing the latest AV products and technologies.

“It’s going to get bigger and better. As a matter of fact, our Chicago E4 in May was our largest ever,” stated Taylor. The fact is that the Exertis Almo team is coming together to expand the expo by securing larger venues that will give vendors more space to showcase their products and services.

Taylor also noted that they are not necessarily bringing in more vendors as the relationships presently established are very strong. Of course, both former organizations are now collaborating with vendors they had not used before as this is what is best for their clients.

Even better, having gone fully hybrid for the first time in 2021 during the Dallas, TX event, the company has decided to move forward with this model as it maximizes access for AV professionals to attend events and learn of the latest developments no matter where they are in the world.

These are no doubt exciting times with Exertis Almo posed to take the AV industry by storm.

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More